Literature DB >> 27910111

Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly.

Anna Aulinas1,2, Iris Crespo1, David Viladés3, Ruben Leta3, Eulàlia Urgell4, Betina Biagetti5, Susan M Webb1, Elena Valassi1.   

Abstract

BACKGROUND: Acromegaly (ACRO) is associated with elevated cardiovascular risk, although the prevalence of coronary artery disease (CAD) is unclear. Increased epicardial adipose tissue (EAT) and elevated cystatin-C (Cys-C) levels are cardiovascular risk factors, also related to the progression of CAD in several populations. AIMS: To measure the severity and extent of CAD in patients with ACRO and to determine whether either EAT or Cys-C reflect higher cardiovascular risk in patients with ACRO than in healthy controls. SUBJECTS AND METHODS: Case-control study, of 35 patients with ACRO (19 males, 17 with active disease) and 35 age-, gender- and body mass index (BMI)-matched healthy controls; mean age was 48·1 ± 8·1 years and mean BMI was 27·6 ± 4·8 kg/m2 . Cys-C was measured by an immunoturbidimetric assay. The 10-year risk of developing a coronary event was calculated using the Framingham Risk Score (FRS). EAT index (volume indexed to body surface area), and severity and extent of CAD were measured using a 256-slice multidetector computed tomography scanner (iCT-256 Philips Healthcare, Amsterdam).
RESULTS: Coronary artery disease lesions, EAT index and severity/extent of CAD were similar between patients with ACRO and controls. Forty-four per cent of patients with ACRO had mild coronary lesions associated with greater EAT index (ß = 0·022, P = 0·036). Cys-C levels correlated with both EAT index (ρ = 0·386, P = 0·031) and FRS (ρ = 0·477, P = 0·004) in patients with ACRO only, despite similar prevalence of traditional cardiovascular risk factors. In a multiple linear regression model, both Cys-C levels (ß = 0·369, P = 0·007) and EAT index (ß = 0·29, P = 0·025) predicted FRS (R2 = 0·613).
CONCLUSIONS: In patients with ACRO, both Cys-C and EAT index might be used as noninvasive predictors of cardiovascular risk.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27910111     DOI: 10.1111/cen.13273

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?

Authors:  M Demirpence; A Guler; H Yilmaz; A Sayin; Y Pekcevik; H Turkon; A Colak; E M Ari; B Aslanipour; G U Kocabas; M Calan
Journal:  J Endocrinol Invest       Date:  2018-05-26       Impact factor: 4.256

2.  Association of epicardial adipose tissue with serum level of cystatin C in type 2 diabetes.

Authors:  Tomomi Murai; Noriko Takebe; Kan Nagasawa; Yusuke Todate; Riyuki Nakagawa; Rieko Nakano; Mari Hangai; Yutaka Hasegawa; Yoshihiko Takahashi; Kunihiro Yoshioka; Yasushi Ishigaki
Journal:  PLoS One       Date:  2017-09-18       Impact factor: 3.240

3.  Cre/CysC ratio may predict muscle composition and is associated with glucose disposal ability and macrovascular disease in patients with type 2 diabetes.

Authors:  Qing Yang; Mei Zhang; Peng Sun; Yanying Li; Huichao Xu; Kejun Wang; Hongshan Shen; Bo Ban; Fupeng Liu
Journal:  BMJ Open Diabetes Res Care       Date:  2021-11

4.  Association of Epicardial Adipose Tissue Thickness with Cardiovascular Risk in Acromegaly.

Authors:  Bulent Can; Fatma Olcay Coskun; Sercin Ozkok; Mumtaz Takir
Journal:  Medeni Med J       Date:  2022-06-23

5.  Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice.

Authors:  Betina Biagetti; J R Herance; Roser Ferrer; Anna Aulinas; Martina Palomino-Schätzlein; Jordi Mesa; J P Castaño; Raul M Luque; Rafael Simó
Journal:  J Clin Med       Date:  2019-09-26       Impact factor: 4.241

6.  Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients.

Authors:  Marta Ragonese; Gianluca Di Bella; Federica Spagnolo; Loredana Grasso; Angela Alibrandi; Guiseppe Giuffrida; Mariacarla Moleti; Francesco Ferraù; Salvatore Cannavò
Journal:  Exp Clin Endocrinol Diabetes       Date:  2021-12-23       Impact factor: 2.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.